Post by Dr. Reddy's and Nestlé Health Science Limited

Excited to share a significant milestone in metabolic care with the pan-India launch of Celevida GLP+ by Dr Reddy's Nestlé Health Science. As India continues to face a growing burden of obesity and diabetes, the focus must go beyond weight loss. With the unique "thin-fat Indian phenotype", preserving muscle mass during GLP-1 and GIP therapies is critical in Indians especially since we have genetically low muscle mass and higher fat mass. Also, intake of protein from diet is lower than recommended Studies have indicated that 25-40% of total weight loss is from lean body mass for people on GLP-1/GIP therapy, which further reinforces the need for higher protein intake along with maintaining healthy lifestyle. Celevida GLP+ addresses this gap with a high-protein formulation (48g/100g), enriched with whey protein isolate and 100% RDA of Branched chain amino acids (BCAAs) to support muscle preservation along with vitamins & minerals. With a strong nationwide rollout, this launch reinforces a science-led, integrated approach to obesity and diabesity care. 👉Connect with your healthcare partners today to explore how Celevida GLP+ can be integrated into your patient management approach. 👉Start the conversation on combining nutrition and therapy for better long-term outcomes. Here's what the media has to say - https://lnkd.in/gYVh2Die https://lnkd.in/gRVAeT7g #Healthcarelnnovation #GLP1 #DiabetesCare #ObesityManagement #NutritionMatters #ScalingNewHorizons Shantaprasad Nagarmath Mansi Khanna Vinay Lakhotia Aaron Trevor DSouza Belji Kuriakose Prateek Pant Atriman Das Mayank Bedi Dr. Nandan Joshi Shariq Mamsa Anil Guntupalli Dr. Rachana Bhoite Sailaja V. Sukhada Bhatte Manish Bajaj Paresh Wani